(Q38796312)

English

Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia

scientific article published on April 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 September 2017

Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia (English)

1 reference

Europe PubMed Central

6 September 2017

1 reference

based on heuristic

inferred from title

metabolic syndrome

1 reference

based on heuristic

inferred from title

atherosclerosis

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum to: Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.

0 references

author name string

Nicola Ferri

1

1 reference

Europe PubMed Central

6 September 2017

Massimiliano Ruscica

2

1 reference

Europe PubMed Central

6 September 2017

publication date

1 April 2016

1 reference

Europe PubMed Central

6 September 2017

1 reference

Europe PubMed Central

6 September 2017

54

1 reference

Europe PubMed Central

6 September 2017

588-601

1 reference

Europe PubMed Central

6 September 2017

3

1 reference

Europe PubMed Central

6 September 2017

https://scigraph.springernature.com/pub.10.1007/s12020-016-0939-0

0 references

Metabolic syndrome pandemic.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The regulation of ApoB metabolism by insulin

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

How to screen obese children at risk for type 2 diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Insulin resistance and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Targeting inflammation in metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Adipocyte dysfunction, inflammation and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The PCSK9 decade

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Precursor convertases in the secretory pathway, cytosol and extracellular milieu

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9 function and physiology.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The LDL receptor

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Molecular basis for LDL receptor recognition by PCSK9

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

SREBP transcription factors: master regulators of lipid homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Resistin: insulin resistance to malignancy

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Genetic and metabolic determinants of plasma PCSK9 levels

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

A new method for measurement of total plasma PCSK9: clinical applications

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Fructose and metabolic diseases: new findings, new questions

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The effect of insulin on circulating PCSK9 in postmenopausal obese women

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Statin therapy and related risk of new-onset type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Role of PCSK9 beyond liver involvement

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The role of the LDL receptor in apolipoprotein B secretion

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Small dense LDL: An emerging risk factor for cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The composition and metabolism of large and small LDL.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes melli

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docosahexaenoic Acid Attenuates Cardiovascular Risk Factors via a Decline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Plasma Levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HNF1alpha and SREBP2 are important regulators of NPC1L1 in human liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Québec Child and Adolescent Health and Social Survey: design and methods of a cardiovascular risk factor survey for youth

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are pleiotropic effects of statins real?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12020-016-0939-0

1 reference

Europe PubMed Central

6 September 2017

release_ud43oc2amjfkpkman4ycwjy3je

1 reference

https://api.fatcat.wiki/v0/release/ud43oc2amjfkpkman4ycwjy3je

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

6 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38796312&oldid=1837803506"